NCT04539301View on ClinicalTrials.gov

Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

RecruitingOBSERVATIONAL
Enrollment

2,100

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

May 1, 2024

Study Completion Date

May 1, 2024

Conditions
AnticoagulationVenous ThromboembolismAtrial Fibrillation
Interventions
DIAGNOSTIC_TEST

Estimated anticoagulant level (conversion factor x anti-Xa activity)

Estimated anticoagulant level (conversion factor x anti-Xa activity)

Trial Locations (1)

44093

RECRUITING

Nantes University Hospital, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER